Hydrochloric Acid Lock Therapy for Central Line-associated Bloodstream Infections

Inclusion criteria * Patients aged 0-17 years treated at pediatric oncologic department at Copenhagen University Hospital, Odense University Hospital, and Aarhus University Hospital, Denmark. Inclusion of children and adolescents from 1st of June 2022. * Patients aged 18-100 years treated at Department of Hematology, Copenhagen University Hospital, Denmark. Inclusion of adult patients from 17th of October 2023. * Patients receiving treatment for cancer or a hematologic disease (any type and at any point in the course of the disease). * CVAD in situ (intravenous ports and all central lines). * New diagnosis of CLABSI (defined as a laboratory-confirmed bloodstream infection, not secondary to infection at another site, in a patient who has a CVAD). NB, patients who had a CLABSI prior to the beginning of the study are accepted for enrollment if they have a new CLABSI during the patient enrollment phase. The patient is followed 6 weeks from instillation with HALT/placebo. The patient can be re-included if the patient has 1) replacement of the CVAD, or 2) a new CLABSI later than 6 weeks from a previous CLABSI. In case of re-inclusion the patient, the patient will be randomized again. Exclusion Criteria: * Plan to remove CVAD within 6 days. * Instantly admission to Intensive Care Uni